All Stories

  1. Harnessing Venetoclax in NPM1-Mutated AML: A Path to Sustained Remission and Beyond
  2. Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus
  3. SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma
  4. The Evolving Role of Hematopoietic Stem Cell Transplantation in Philadelphia-like Acute Lymphoblastic Leukemia: From High-Risk Standard to Precision Strategies
  5. CAR-T Cell Therapies in B-Cell Acute Lymphoblastic Leukemia: Emerging Data and Open Issues
  6. CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy
  7. Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study
  8. Treatment Strategies Used in Treating Myelofibrosis: State of the Art
  9. First-Line Use of Daratumumab in Patients with Multiple Myeloma Shows Delayed Neutrophil and Platelet Engraftment after Autologous Stem Cell Transplantation: Results from a Real-Life Single-Center Study
  10. Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?
  11. OBITUARY- Riccardo Saccardi (20th April 1956–19th February 2024)
  12. Integrating CAR-T cell therapy into the management of DLBCL: what we are learning
  13. The Role of MicroRNA in Graft-Versus-Host-Disease: A Review
  14. Refractory CMV infection in post-transplant phase: epidemiological framing in the Italian context, current patient management and unmet needs
  15. Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation
  16. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation
  17. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial
  18. Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party
  19. Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?
  20. Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon
  21. Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide
  22. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT
  23. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
  24. Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation
  25. Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01
  26. Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy
  27. GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms
  28. Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT
  29. The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML
  30. Biological Significance and Prognostic Value of Cytogenetics in 160 Patients with Multiple Myeloma: Predictivity of 13 and/or 14 Monosomies
  31. Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial
  32. Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial
  33. Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study
  34. Real-Life CAR-T Cell Treatment in Large B-Cell Lymphomas Indicates That Axi-Cel and Tisa-Cel Have Similar Outcomes, but Long-Term Cytopenia Is an Emerging Problem
  35. The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
  36. Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study
  37. Identifying and managing CAR T-cell–mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team
  38. Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience
  39. The role of pharmacies in haematopoietic stem cell transplantation process: A nationwide survey by Gruppo Italiano Trapianto di Midollo Osseo
  40. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience
  41. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
  42. CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
  43. Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellular...
  44. Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study
  45. Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey)
  46. The Burden in Caregivers of Multiple Myeloma Patients Undergoing Outpatient Autologous Stem-Cell Transplantation Compared to Inpatient Transplantation
  47. The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study
  48. Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT
  49. Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study
  50. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
  51. Chemotherapy-based regimens in multiple myeloma in 2020
  52. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
  53. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma
  54. Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?
  55. Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission
  56. Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety
  57. Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art
  58. A Patient with Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia and Multiple Myeloma
  59. Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT
  60. Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT
  61. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis
  62. Impact of donor age and kinship on clinical outcomes after T-cell–replete haploidentical transplantation with PT-Cy
  63. Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report
  64. Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia
  65. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party
  66. Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria)
  67. Manipulation, and cryopreservation of autologous peripheral blood stem cell products in Italy: A survey by GITMO, SIDEM and GIIMA societies
  68. Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody—Begelomab
  69. Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials
  70. Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost
  71. A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant
  72. An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma
  73. Bone Marrow Versus Mobilized Peripheral Blood Stem Cells for Non T Depleted Haploidentical Transplantations with Post Transplantation Cyclophosphamide in Acute Lymphoblastic Leukemia: On Behalf of the ALWP of the EBMT
  74. Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34+ Cell and Platelet Counts
  75. Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials
  76. Individualized prediction of leukemia‐free survival after autologous stem cell transplantation in acute myeloid leukemia
  77. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update
  78. The use of ibrutinib before and after allogeneic stem cell transplantation
  79. Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials
  80. Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease: A Study on Behalf of the Acute Leukemia Working Party of EBMT
  81. Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score
  82. Venetoclax for the treatment of chronic lymphocytic leukemia
  83. Can we improve the conditioning regimen before autologous stem cell transplantation in multiple myeloma?
  84. A Comparative Assessment of Quality of Life in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model
  85. Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model
  86. A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach
  87. Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma
  88. Chemotherapy and Cardiotoxicity in Hematologic Malignancies
  89. Basal CD34+ Cell Count Predicts Peripheral Blood Stem Cell Mobilization in Healthy Donors after Administration of G-CSF: a Longitudinal, Prospective, Observational, Single-Center, Cohort Study
  90. Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012
  91. Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation
  92. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy
  93. Sorafenib for the treatment of multiple myeloma
  94. Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma
  95. The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma
  96. High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry
  97. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents
  98. The role of tandem stem cell transplantation for multiple myeloma patients
  99. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantatio...
  100. A Phase 2 Study of Bendamustine Plus Melphalan Conditioning for Second Autologous Stem Cell Transplantation in "De-Novo" Multiple Myeloma Patients in a Tandem Transplant Strategy
  101. Fast and Non-Invasive Identification of Tumorigenic-Proliferative Biomarker in Myeloproliferative and Lymphoproliferative Disorders
  102. Results and Cost Effectiveness of "on-Demand" Plerixafor Added to Chemotherapy and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Multiple Myeloma
  103. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for “De Novo” Multiple Myeloma Patients: A Phase II Study
  104. Polycythemia following allogeneic hematopoietic progenitor cell transplantation occurring during iron chelation therapy
  105. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients
  106. Breast cancer circulating biomarkers: advantages, drawbacks, and new insights
  107. Mobilization of Hematopoietic Stem Cells with Lenograstim in Healthy Donors: Efficacy and Safety Analysis According to Donor Age
  108. High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer
  109. Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity
  110. Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs
  111. Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice-daily dosing: a single-center prospective study with historical control
  112. Smoldering multiple myeloma: to treat or not to treat
  113. Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
  114. Bendamustine Plus Melphalan As Conditioning Regimen for Second Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Single Centre Experience
  115. Biosimilar Compared with Originator Filgrastim for Autologous Stems CELL Mobilisation: A Prospective-Historical Control Study in Multiple Myeloma REAL-Life Setting
  116. Homozygosity for Killer Immunoglobin-like Receptor (KIR) Haplotype a Is Associated to Negative Interim Positron Emission Tomography (PET) and a Favourable Outcome in Hodgkin Lymphoma
  117. Tolerability and Efficacy of Busulfan and Fludarabine As Allogeneic Pretransplant Conditioning Therapy in Acute Myeloid Leukemia: Comparison With Busulfan and Cyclophosphamide Regimen
  118. Autologous stem cell transplantation in multiple myeloma is not dead but alive and well
  119. Plerixafor: what we still have to learn
  120. Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation
  121. High-dose chemotherapy for germ cell tumors: do we have a model?
  122. A home-care, early discharge model after autografting in multiple myeloma: results of a three-arm prospective, non-randomized study
  123. Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study
  124. The effectiveness of therapy with octreotide LAR in combination treatment with zoledronic acid versus zoledronic acid alone.
  125. Role of new drugs incorporated into consolidation and maintenance therapy in transplant-eligible multiple myeloma patients
  126. Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs
  127. Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry
  128. Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization
  129. Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: results of an Italian multicenter study
  130. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs
  131. An old drug with a new future: bendamustine in multiple myeloma
  132. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma
  133. Diagnostic approaches for identifying acute graft-versus-host disease: what comes next?
  134. Optimizing Outcomes Following Allogeneic Hematopoietic Progenitor Cell Transplantation in AML: The Role of Hypomethylating Agents
  135. Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma
  136. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma
  137. Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients
  138. Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry
  139. Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program
  140. Are there still reasons to believe that high-dose chemotherapy has a role in breast cancer management?
  141. Extracorporeal photopheresis, a therapeutic option for cutaneous T-cell lymphoma and immunological diseases: state of the art
  142. A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease
  143. Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear?
  144. Plerixafor Added to Chemotherapy Plus G-CSF Is Safe and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or Lymphoma
  145. Internal Iliac Artery Perforation following Bone Marrow Aspiration in a Patient with No Previously Identified Risk Factors: A Case Report and Review of the Literature
  146. Imatinib mesylate in T-cell large granular lymphocyte leukemia associated with chronic graft-versus-host disease
  147. Pulmonary micro-embolism in a healthy donor following G-CSF administration for mobilization of hemopoietic progenitor cells
  148. Single/tandem autologous hematopoietic progenitor cell transplantation in high-risk de novo multiple myeloma patients: A retrospective analysis.
  149. Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience
  150. Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for breast cancer with > 9 positive nodes: 15-year results from the Italian registry
  151. Allogeneic hemopoietic stem cells donor complications: A single institution survey on sibling donors mobilized with G- CSF
  152. r-HuEPO 40,000 U one time/week before high-dose melphalan allows a tandem autologous peripheral stem-cell transplantation without red blood cell transfusion in multiple myeloma patients: A pilot study
  153. Utility of the Clinical Practice of Admnistering Thrombophilic Screening and Antithrombotic Prophylaxis with Low-Molecular-Weight Heparin to Healthy Donors Treated with G-Csf for Mobilization of Peripheral Blood Stem Cells
  154. Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients
  155. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients
  156. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients
  157. Predictive factors that affect the mobilization of CD34+cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF)
  158. Different γ/δ T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation
  159. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study
  160. Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting
  161. Modification of the content of plasma protein carbonyl groups in donors after granulocyte colony stimulating factor-induced stem cell mobilization
  162. 'In vivo' time course of plasma myeloperoxidase levels after granulocyte colony-stimulating factor-induced stem cell mobilization
  163. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation
  164. Harvesting peripheral blood progenitor cells from healthy donors with a short course of recombinant human granulocyte-colony-stimulating factor
  165. Wernicke's encephalopathy after allogeneic stem cell transplantation
  166. Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim
  167. Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients
  168. High-Dose Chemotherapy with Mitoxantrone + Melphalan and Autologous Stem Cell Rescue in Metastatic Breast Cancer Patients: A Study of Feasibility and Tolerability
  169. Differences in Transplant-Related Complications between Hematologic Malignancies and Solid Tumors Receiving High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation
  170. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients
  171. Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy
  172. HIGH-DOSE ETOPOSIDE ENABLES THE COLLECTION OF PERIPHERAL BLOOD STEM CELLS IN PATIENTS WHO FAILED CYCLOPHOSPHAMIDE-INDUCED MOBILIZATION
  173. Technical note: Chromosomal and mtDNA analysis of Oliver
  174. Implications of solar flare charged particle, gamma ray and neutron observations: Rapporteur Paper II for the High Energy Solar Physics Workshop